HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries
- Elliot Marseille1Email author,
- Lalit Dandona2,
- Nell Marshall1,
- Paul Gaist3,
- Sergio Bautista-Arredondo4,
- Brandi Rollins1,
- Stefano M Bertozzi4,
- Jerry Coovadia5,
- Joseph Saba6,
- Dmitry Lioznov7,
- Jo-Ann Du Plessis5,
- Evgeny Krupitsky7,
- Nicci Stanley5,
- Mead Over9,
- Alena Peryshkina10,
- SG Prem Kumar11,
- Sowedi Muyingo12,
- Christian Pitter8,
- Mattias Lundberg13 and
- James G Kahn1
© Marseille et al; licensee BioMed Central Ltd. 2007
Received: 02 April 2007
Accepted: 12 July 2007
Published: 12 July 2007
Economic theory and limited empirical data suggest that costs per unit of HIV prevention program output (unit costs) will initially decrease as small programs expand. Unit costs may then reach a nadir and start to increase if expansion continues beyond the economically optimal size. Information on the relationship between scale and unit costs is critical to project the cost of global HIV prevention efforts and to allocate prevention resources efficiently.
The "Prevent AIDS: Network for Cost-Effectiveness Analysis" (PANCEA) project collected 2003 and 2004 cost and output data from 206 HIV prevention programs of six types in five countries. The association between scale and efficiency for each intervention type was examined for each country. Our team characterized the direction, shape, and strength of this association by fitting bivariate regression lines to scatter plots of output levels and unit costs. We chose the regression forms with the highest explanatory power (R2).
Efficiency increased with scale, across all countries and interventions. This association varied within intervention and within country, in terms of the range in scale and efficiency, the best fitting regression form, and the slope of the regression. The fraction of variation in efficiency explained by scale ranged from 26% – 96%. Doubling in scale resulted in reductions in unit costs averaging 34.2% (ranging from 2.4% to 58.0%). Two regression trends, in India, suggested an inflection point beyond which unit costs increased.
Unit costs decrease with scale across a wide range of service types and volumes. These country and intervention-specific findings can inform projections of the global cost of scaling up HIV prevention efforts.
There is wide agreement that an effective response to the global HIV epidemic requires very substantial resources. This consensus has been partially translated into increasing contributions to combat the epidemic . Aggregate commitments by major donors such as the Global Fund to Fight Malaria, TB and HIV; the U.S. President's Emergency Program for AIDS Relief (PEPFAR); the European Union; and, the Gates Foundation suggest that we have entered an era in which the total funds allocated to stem the HIV epidemic may constitute a significant portion of the amount needed. Yet the imperative to spend this money efficiently can hardly be over-stated: the lives of millions depend upon how effectively available funds are allocated. Sound resource allocation and program budgeting, in turn, must rest on a foundation of robust unit cost estimates for the most important prevention modalities in key epidemic and cultural settings.
There is a substantial, growing, but still limited body of data on the costs of HIV prevention services [2–12]. These data provide a reasonable basis for estimating service costs for some intervention types in some settings, particularly in sub-Saharan Africa. However many other intervention-setting pairs remain unexamined. In addition to an insufficient number of cost data points, data have often been gathered using different data collection instruments and compiled using different methods. These data are therefore not always directly comparable.
Micro-economic theory and empirical evidence suggest that under ordinary circumstances downward sloping average total costs flatten out and eventually turn up to form a U-shaped curve . While the concept of diseconomies of scale was originally developed in conjunction with the theory of the firm [14, 15], the causes of scale diseconomies are not specific to the private sector. These causes include increasing costs of communication, increasing worker alienation, bureaucratic inertia, and duplication of effort. Certain inputs may become more costly too. For example, at least over the short term, a program may exhaust the available supply of lower-wage but adequately trained staff in the area, and be forced to hire staff that are more expensive. On the demand side, after the most willing and accessible clients have been served, it becomes increasingly expensive to reach and motivate the next client. Information concerning the threshold beyond which unit costs increase can help inform plans for program expansion . For example, they can help to determine whether it is more efficient to cover a given area with fewer, but larger HIV prevention facilities, or with a larger number of smaller facilities.
While cost data are limited, still less is understood about how HIV program expansion affects costs and effectiveness. Among the unanswered questions, are: "How rapidly do costs decline with scale? How does the strength of the relationship between unit cost and scale vary by intervention and by country? At what service volume do unit costs start to rise again?" In the absence of data on scale effects, efforts to project resource requirements for scaled-up HIV/AIDS programs assume constant unit costs and vary this assumption in sensitivity analyses [17, 18]. It is understood that the assumption of constant unit costs may result in substantial inaccuracies . We are aware of only one empirical study of the relationship between scale and unit costs of an HIV prevention program. This analysis of the effect of scale on total and on unit costs in 17 sex worker programs run by non-governmental organizations in southern India found decreasing unit cost up to about 1,000 – 1,700 sex workers served annually, after which unit costs rise in a classic U-shaped curve . In a 2005 review of the costs of scaling up health interventions in developing countries, the authors found that there were insufficient data to support their goal of deriving typical unit cost curves as interventions increase in scale .
"Prevent AIDS: Network for Cost-Effectiveness Analysis" (PANCEA) is a five-country study funded by the U.S. National Institutes of Health. It has the purpose of providing essential information and analysis for an improved allocation of HIV prevention funds in low and middle-income countries. The study includes five countries: India, Mexico, Russia, South Africa, and Uganda. The results presented here draw on PANCEA data to describe the relationship of program efficiency (unit cost) and scale (number of units of services delivered). The PANCEA analysis ultimately aims to measure cost-effectiveness, i.e., the cost per "outcome" such as HIV cases averted. The present study assesses efficiency in the production of "outputs" such as the number of clients served, that are the proximate cause of behavior change and thus of epidemic impact.
PANCEA design and data collection methods have been detailed previously and are summarized here .
Number and type of HIV prevention sites utilized in the analysis of relationship between scale and unit costs
Russia – Pavlov
Russia – AI
Data on Outputs and Costs
We developed an integrated set of data collection instruments to portray program operations with sufficient detail and flexibility to capture variation among nominally similar program types, and with sufficient standardization to permit valid comparisons across multiple programs.
Key outputs used for analysis of variation in unit cost by scale
Clients receiving VCT counseling* & testing
Hours of contact with program clients
First visits for suspected STI
IDU risk reduction
Client-year of needles (weekly)
Hours of media exposure
Women receiving post-test counseling
We conducted a comprehensive assessment of the costsof running HIV prevention interventions. Cost instruments were extensively adapted from templates produced by others to add a time element and pre-specified inputs specific to the interventions. The instruments record data on resources used and expenditures. Cost data were collected in five standard categories: personnel (clinical and support), recurrent goods (e.g., test kits), recurrent services (e.g., utilities), capital (e.g., computers and vehicles), and building or other operating space (purchase or rental). The instruments were piloted and revised, and programmed into Excel and MS Access. We costed all donated inputs (i.e., employed economic rather than financial costing), using unit costs for inputs as determined by local price quotes.
Data collection was co-coordinated by a group at the University of California, San Francisco (UCSF), and conducted in 2003 and 2004 by local HIV research teams. These teams were selected based on a prior record of high quality data collection and analysis, ability to assemble an appropriately skilled and managed team, and network of contacts among HIV prevention agencies. In-country collaborative teams were India (Administrative Staff College of India), Mexico (Instituto Nationale de Salud Publica), Russia (Pavlov University and AIDS Infoshare); South Africa (HIVAN and Axios International), and Uganda (Axios International). Each team underwent a two-week training program, including theoretical and practical components.
Each HIV prevention program site studied required seven to twelve person-days of work, including initial and follow-up visits. All data were reviewed by the UCSF team to identify gaps and inconsistencies, which were resolved through written and telephonic queries posed to the local research teams. Data verification visits were conducted at 10 percent of sites (typically 4 per country) to verify the accuracy of PANCEA data. Half of the sites were chosen based on surprising or interesting findings. The other half were chosen randomly. During these visits, local and UCSF team members reviewed and resolved potential problems and all key output and cost data.
We used written project records when available. For example, VCT programs usually have detailed records on the specific intervention steps such as pre-test counseling and HIV tests administered. However, available documents were often incomplete or imperfectly matched to PANCEA instruments, and thus required interpretation by respondents to provide needed data. Without inclusion of these less formal data sources, many HIV prevention programs would have been excluded; we were willing to sacrifice some precision for a more inclusive portrayal of the universe of HIV prevention programs. Some programs showed an imperfect match between the number of HIV test kits acquired and the number used in a given time period. In sites that had a greater than 10% discrepancy between the number reported to have been acquired and the number of tests administered, we assigned test kit costs according to the number used augmented by 10% to account for wastage.
The cost of each program is defined as the sum of all inputs (resources) multiplied by the unit costs for these inputs. We relied on financial data if a market price was paid by the program, otherwise on market value. We report in detail elsewhere on the methods and results for program total costs and cost per key output, including by category of cost [10, 22] The analysis here focuses on the relationship of program scale and efficiency (cost per key output).
Scaleis defined as the quantity of key outputs delivered during a 12-month period (the most recent full fiscal year available). The key outputs are listed in Table 2. We determined scale directly from key output data (e.g., number of individuals receiving VCT services to post-test counseling), or calculated it based on the mix of different services and the frequency, average duration, and number of participants for each (e.g., sex worker programs).
Program costis defined as the total value of resources used to deliver program services for the same 12-month time period. This is "economic cost", i.e., includes financial expenditures as well as the market value of donated or subsidized inputs (such as volunteer labor or donated test kits). Costs in local currencies were converted into US$ based on the average exchange rate in the year for which data are presented.
Efficiency(or cost per key output) is defined as the program cost divided by the scale. There is no adjustment for potential savings due to HIV infections averted.
We examined the association between scale and efficiency for all programs of an intervention type within each country. We characterized the direction, shape, and strength of association by applying all of the bivariate regression forms available in MS Excel, which include linear, logarithmic, polynomial, power, and exponential. We chose and present the regression form which yielded the highest R-square values. Due to the multiplicity of relationships examined, and to maintain a focus on scale, we did not perform multi-variate regressions for this overview analysis. We graphed efficiency versus scale using ordinal and abscissa scales (linear or logarithmic) that portray the range of results for each intervention most clearly.
Service delivery quality
Quality of services could explain a portion of the potential association between unit cost and volume. For the 86 VCT sites, we therefore performed constructed a regression model to examine the association between quality indicators and unit cost. The independent variables included features of service delivery (i.e., duration of pre-test and post-test counseling sessions, availability of supplies, length of time clients waited to see a counselor, and the turn-around time for tests results), management (i.e., use of formal service delivery protocols, staff training, extent to which operations were monitored including politeness to clients, following protocol, use of performance incentives and penalties) and evaluation (i.e., whether an independent evaluation had ever been conducted, how often and for what purposes). The main model also included dummy variables for country. In an additional model, unit costs were adjusted for purchasing power parity.
Ethics committee approval
The University of California, San Francisco's Committee on Human Research, approved this study.
We found that efficiency increased (unit costs decreased) with scale, across all countries and interventions we examined. This association varies within intervention and country, in terms of the observed range in efficiency and scale, the type of regression equation that provides the best fit, and slope of the regression line, and the proportion of variation in efficiency explained by scale. Of the 15 country-intervention pairs studied, the regression lines for two, STI and MTCT programs in India, suggest an inflection point beyond which we expect to see an up-turn in unit costs. Of these two, only one, the regression line for MTCT programs, was statistically significant. With simple linear functions, the regression trends were downward sloping in all cases.
Strength of the relationship and coefficient of determination between unit cost and program scale
Unit cost decrease associated with doubling of scale 1
p-value of regression
Coefficient of determination (R2)
Unit cost decrease associated with doubling of scale 1
p-value of regression
Coefficient of determination (R2)
Unit cost decrease associated with doubling of scale 1
p-value of regression
Coefficient of determination (R2)
Voluntary Counseling and Testing Programs
VCT unit cost and quality
We found no statistically significant relationship between any of our VCT program quality indicators and unit cost. The R-square for the full model, which included dummy variables for countries and adjustments for purchasing power parity was 0.05, suggesting that quality, as reflected in our analysis, explains almost none of the variation in observed unit costs.
Sex Worker Programs
Sexually Transmitted Infection programs
Information, Education and Communication programs
Risk reduction programs
Data on risk reduction program for injection drug users come only from Russia. Most programs focus on needle-syringe exchange. For these programs, scale varies 50-fold, and efficiency varies 40-fold. Scale explains 45% of variation in efficiency (cost per 50 needles exchanged). A doubling in scale is associated with a 34.5% reduction in cost per output (p-value = 0.004).
Prevention of Mother to Child Transmission programs
With two exceptions, we found increasing efficiency across the full range of scale examined, in each of the 16 country-intervention pairs. Although the shape and strength of the association varied by country and intervention type, we found cost per key output and scale to be strongly and negatively correlated in almost all instances – with the fraction of variation in efficiency explained by scale ranging from 19% – 96%. Doubling in scale resulted in reductions in unit costs averaging 34.2% across all country-intervention pairs and ranging from 2.4% to 56%.
Over the scale that we examined, we saw no up-turn in cost per key output except for STI and PMTCT programs in India. The latter was due to only one data point (Figure 6). This suggests that for programs in similar demographic and epidemic settings one would expect to observe increasing efficiency at least up to similar levels of output. This is an encouraging finding as it suggests that the current global HIV prevention program will become less costly over a wide range of expansion. However, this finding must be tempered by the finding of an up-turn in unit cost reported in the previous study of SW programs in India , and by the up-turn reported here in PMTCT and STI programs. It must also be tempered by unpublished data from India by co-author Dandona using PANCEA methods for a more recent fiscal year that suggest an up-turn for VCT and SW programs. However, it is important to note that with simple linear functions, the regression trends were downward sloping in all cases.
There are a number of possible and non-mutually exclusive causes of the systematic economies of scale observed in the PANCEA data. One is that busier facilities are able to distribute their fixed costs over more cases, thus lowering their unit costs. A second is that busier facilities are better positioned to take advantage of potential lower prices through bulk purchases, sharing of services and other advantages of scale that lead to greater efficiency. Yet a third mechanism by which large scale may reduce unit costs is that program administrators learn how to integrate HIV prevention activities with routine services, reduce personnel "down-time," reduce supply loss and breakage, and generally deploy their resources more efficiently. This learning occurs over time and is thus an "economy of time" rather than of scale per se. However, in an era of program expansion, time and scale are highly correlated.
The first explanation, i.e., that unit costs decline as fixed costs are distributed over more output, is an arithmetic and programmatic truism, and therefore must contribute to the observed scale effects. The extent of that contribution depends on the portion that fixed costs constitute of total costs. The larger the fixed cost portion, the stronger the scale effect will be. Thus, it may be possible to increase efficiency by either increasing demand for services or finding ways to reduce costs that have been treated as fixed. Because inputs were market priced, we introduced a bias toward not being able to detect economies of scale arising from the ability to make bulk purchases. The third explanation, namely that program managers learn how to optimize deployment of the resources over time, and thus with scale, is supported by longitudinal analyses we conducted in PANCEA and other analyses we are conducting  (and unpublished data).
The purpose of the current analysis was to document the relationship between scale and unit cost and not to formally assess the relative contribution of each of these three causes. Our team is planning further analyses of the underlying determinants of efficiency using multivariate regression techniques to shed light on this question. We are currently analyzing longitudinal data on about 20% of the PANCEA sites and applying multivariate analyses to the existing data set in an effort to address these questions more definitively.
Our analysis has a number of important limitations. The data presented here are cross-sectional. Rather than documenting the change in unit costs over time within expanding programs, we tabulated the unit costs of many programs simultaneously and measured the association between scale and unit costs among them. Although these analyses are strongly suggestive of economies of scale within programs, they do not demonstrate it directly. In addition, this study does not use multivariate statistical methods to show the relative contribution of other possible predictors of unit costs, or to control for possible confounding factors. In particular, this paper does not assess the possible role of service quality as a mediator between unit cost and service volume. The effects of quality on unit costs are unclear. Higher quality services may require more resources and thus raise costs. It may also increase a programs reputation, thereby lowering outreach and promotion costs. By attracting more clients, it may also contribute to lowering unit costs via other economy of scale effects. We did not observe service delivery directly, and meaningful measures of quality vary by intervention type. However, for VCT programs, the largest program sub-set, we regressed cost per client on numerous indicators of program quality. We found no statistically significant associations between indicators of service quality and unit costs. For these reasons, it is conceivable, if unlikely, that the differences observed reflect program differences other than scale, but reflected in scale.
Because we did not observe an upturn in unit costs with larger scale for the vast majority of the programs, we are unable to address the question of what the optimal size of different types of prevention modalities might be. That is, we cannot identify optimal facility size, i.e., when it is more efficient to open a new facility in a nearby community rather than continue to expand services in an existing one. We believe that the lesson for now is, more services will usually reduce cost per service. Micro-economic theory suggests that an upturn in unit costs may be a signal to policy makers that the number of HIV prevention service providers should be increased in the relevant setting .
The economies of scale data reported here may contribute to the ongoing effort to project the future cost of the global HIV prevention effort as it scales up. To date these efforts have been hampered by the inability to adjust costs by scale. For the five interventions for which we have a sufficient amount of data, the present findings may be able to provide useful guidance. As more PANCEA-type data are collected by us and by other research teams, it should be possible to add more points to this data set and thus arrive at increasingly precise estimates of the strength and range over which scale effects operate.
Our thanks to Michelle Boontanom, Emily Felt, Adam Nguyen, Raul Reynoso, Ashby Wolfe, and Rudy Rucker at the Graduate School of Public Policy, University of California, Berkeley, for their capable assistance in the analysis of the relationship between VCT service quality and cost. This research was supported by the NIH Task Order #7 contract 282-98-0026 and by the National Institute on Drug Abuse through grant R01 DA15612. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institutes of Health.
- UNAIDS: 2006 report on the global HIV/AIDS epidemic. 2006, Geneva , UNAIDS, 397.
- Kumaranayake L, Watts C: Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa. Aids. 2000, 14 (Suppl 3): S239-52.PubMed
- Creese A, Floyd K, Alban A, Guinness L: Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002, 359 (9318): 1635-1643. 10.1016/S0140-6736(02)08595-1.View ArticlePubMed
- Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA: Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. Bmj. 2005
- Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C, Grinstead O, Coates T: Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania [see comments]. Lancet. 2000, 356 (9224): 113-121. 10.1016/S0140-6736(00)02447-8.View ArticlePubMed
- Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB: Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999, 354 (9181): 803-809. 10.1016/S0140-6736(99)80009-9.View ArticlePubMed
- Kahn JG, Marseille E, Auvert B: Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med. 2006, 3 (12): e517-10.1371/journal.pmed.0030517.PubMed CentralView ArticlePubMed
- Dandona L, Sisodia P, Kumar SG, Ramesh YK, Kumar AA, Rao MC, Marseille E, Someshwar M, Marshall N, Kahn JG: HIV prevention programmes for female sex workers in Andhra Pradesh, India: outputs, cost and efficiency. BMC Public Health. 2005, 5: 98-10.1186/1471-2458-5-98.PubMed CentralView ArticlePubMed
- Dandona L, Sisodia P, Prasad TL, Marseille E, Chalapathi Rao M, Kumar AA, Kumar SG, Ramesh YK, Over M, Someshwar M, Kahn JG: Cost and efficiency of public sector sexually transmitted infection clinics in Andhra Pradesh, India. BMC Health Services Research. 2005, 5: 69-10.1186/1472-6963-5-69.PubMed CentralView ArticlePubMed
- Dandona L, Sisodia P, Ramesh YK, Kumar SGP, Kumar AA, Rao MC, Someshwar M, Hansl B, Marshall N, Marseille E, Kahn JG: Cost and efficiency of HIV voluntary counselling and testing centres in Andhra Pradesh, India. Natl Med J India. 2005, 18: 26-31.PubMed
- McConnel CE, Stanley N, du Plessis JA, Pitter CS, Abdulla F, Coovadia HM, Marseille E, Kahn JG: The cost of a rapid-test VCT clinic in South Africa. S Afr Med J. 2005, 95 (12): 968-971.PubMed
- Soderlund N, Lavis J, Broomberg J, Mills A: The costs of HIV prevention strategies in developing countries. Bull World Health Organ. 1993, 71 (5): 595-604.PubMed CentralPubMed
- Henderson JM, Quandt RE: Micro-Economic Theory: A Mathematical Approach. 1971, New York City , McGraw Hill
- McConnell JL: Corporate Earnings by Size of Firm. Survey of Current Business. 1945, 26 (May): 6-12.
- Stigler JG: The Economies of Scale. Journal of Law and Economics. 1958, 1: 54-71. 10.1086/466541.View Article
- Over M: The effect of scale on cost projections for a primary health care program in a developing country. Soc Sci Med. 1986, 22 (3): 351-360. 10.1016/0277-9536(86)90134-6.View ArticlePubMed
- Stover J, Bertozzi S, Gutierrez JP, Walker N, Stanecki KA, Greener R, Gouws E, Hankins C, Garnett GP, Salomon JA, Boerma JT, De Lay P, Ghys PD: The Global Impact of Scaling-Up HIV/AIDS Prevention Programs in Low- and Middle-Income Countries. Science. 2006
- The World Bank, ACTafrica: Costs of scaling HIV program activities to a national level in sub-Saharan Africa: Methods and Estimates. 2000, Washington, DC , World Bank, 1-44.
- Johns B, Baltussen R: Accounting for the cost of scaling-up health interventions. Health Econ. 2004, 13 (11): 1117-1124. 10.1002/hec.880.View ArticlePubMed
- Guinness L, Kumaranayake L, Rajaraman B, Sankaranarayanan G, Vannela G, Raghupathi P, George A: Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ. 2005, 83 (10): 747-755.PubMed CentralPubMed
- Johns B, Torres TT: Costs of scaling up health interventions: a systematic review. Health policy and planning. 2005, 20 (1): 1-13. 10.1093/heapol/czi001.View ArticlePubMed
- Marseille E, Dandona L, Saba J, McConnel C, Rollins B, Gaist P, Lundberg M, Over M, Bertozzi S, Kahn JG: Assessing the Efficiency of HIV Prevention around the World: Methods of the PANCEA Project. Health Serv Res. 2004, 39 (6 Pt 2): 1993-2012. 10.1111/j.1475-6773.2004.00329.x.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/7/108/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.